Department of Neonatology, Children's Hospital of Fudan University, Shanghai, China.
Department of Clinical Epidemiology, Children's Hospital of Fudan University, Shanghai, China.
J Pediatr. 2021 Dec;239:136-142.e4. doi: 10.1016/j.jpeds.2021.08.067. Epub 2021 Aug 28.
To provide national-level antibiotic use data from Chinese neonatal intensive care units to inform future antimicrobial stewardship using a large contemporary cohort of preterm infants in China.
This retrospective cohort study enrolled all infants less than 34 weeks of gestation admitted to 25 tertiary neonatal intensive care units across China between May 1, 2015, and April 30, 2018. The antibiotic use rate (AUR) was defined as the number of days an infant was prescribed with 1 or more antibiotics divided by the total length of hospital stay.
Among 24 597 eligible infants, 21 736 (88.4%) infants received antibiotics. The median AUR was 441 per 1000 patient-days (IQR, 242-692 per 1000 patient-days). The median duration of each antibiotic course was 9 days (IQR, 6-14 days). Overall, 64.6% infants received broad-spectrum antibiotics, with a median broad-spectrum AUR of 250 per 1000 patient-days (IQR, 0-500 per 1000 patient-days), accounting for 70.7% of all antibiotic use days. Overall, 68.7% of all antibiotic use occurred among infants without infection-related morbidities, with a median duration of 8 days (IQR, 6-13 days) for each course. Only 22.9% episodes of culture-negative sepsis were prescribed with antibiotics for 7 or fewer days, and 34.7% were treated with antibiotics for more than 14 days. For early antibiotic use, the median duration of antibiotic therapy within 7 days after birth was 7 days (IQR, 4-7 days).
A high AUR among infants without infections, prolonged antibiotic durations, and excessive use of broad-spectrum antibiotics were the main problems of antibiotic use in Chinese neonatal intensive care units and should be high-impact focuses for future stewardship interventions.
提供中国新生儿重症监护病房的国家级抗生素使用数据,为未来的抗菌药物管理提供信息,该研究使用了中国 25 家三级新生儿重症监护病房的大量当代早产儿队列。
本回顾性队列研究纳入了 2015 年 5 月 1 日至 2018 年 4 月 30 日期间在中国 25 家三级新生儿重症监护病房住院的所有胎龄小于 34 周的婴儿。抗生素使用率(AUR)定义为婴儿接受 1 种或多种抗生素治疗的天数除以总住院天数。
在 24597 名合格婴儿中,21736 名(88.4%)婴儿接受了抗生素治疗。AUR 的中位数为 441 天/1000 人天(IQR,242-692 天/1000 人天)。每例抗生素疗程的中位数为 9 天(IQR,6-14 天)。总体而言,64.6%的婴儿接受了广谱抗生素治疗,广谱抗生素 AUR 的中位数为 250 天/1000 人天(IQR,0-500 天/1000 人天),占所有抗生素使用天数的 70.7%。总体而言,68.7%的抗生素使用发生在无感染相关并发症的婴儿中,每例疗程的中位数为 8 天(IQR,6-13 天)。仅有 22.9%的培养阴性脓毒症患儿接受了 7 天或更短时间的抗生素治疗,34.7%的患儿接受了超过 14 天的抗生素治疗。对于早期抗生素使用,出生后 7 天内抗生素治疗的中位持续时间为 7 天(IQR,4-7 天)。
无感染婴儿的 AUR 高、抗生素使用时间长、广谱抗生素使用过度是中国新生儿重症监护病房抗生素使用的主要问题,应作为未来管理干预的重点。